XHKG
1498
Market cap16mUSD
Oct 09, Last price
0.24HKD
1D
-1.22%
1Q
-19.33%
Jan 2017
-93.53%
IPO
-94.88%
Name
PuraPharm Corp Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Mainland China, and international markets. Its operations are structured into five key divisions: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers a range of over-the-counter health solutions under brand names such as PuraGold, Haveron, Oncozac, and Immuzac. Beyond product sales, PuraPharm provides a clinic management system for general Chinese medical practices and operates its own chain of Nong's Chinese medicine clinics, which deliver both traditional medical services and CCMG products. The company also oversees the cultivation and trade of raw Chinese herbs, in addition to manufacturing and selling traditional Chinese medicine decoction pieces. Complementing its product offerings, it delivers modernized Chinese medicine services and diagnostic consultations. PuraPharm distributes its goods to hospitals, healthcare institutions, medical professionals, and directly to consumers via an online store. The company currently manages 43 Nong's clinics in Hong Kong and one in Guangxi, China. Founded in 1998, its headquarters are located in Tai Po, Hong Kong.
Key people
Yu Ling Chan
Executive Chairman of the Board, Chief Executive Officer, Founder
Gang Shi
Vice President, Greater China · since 2017
Yuk Chun Ho
General Manager - Nongs Sales and Marketing
Qiong Ruan
General Manager - China Sales and Marketing
Kwun Kiu Cheung
Financial Controller
Biu Tsoi Kam
Executive Director · since 2025
Yee Wai Man
Executive Director · since 2014
Hisayoshi Norimoto
Chief Research and Development Officer, Vice President - Production and Operations in China, Executive Director · since 2020
Charmayne Chan
Company Secretary · since 2021
Zimeng Dong
Non-Executive Director · since 2025
Kwok Keung Leung
Non-Executive Director · since 2023
Non-Executive Independent Director · since 2015
Ting On Hung
Non-Executive Independent Director · since 2025
Non-Executive Independent Director · since 2015
Non-Executive Independent Director · since 2015
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||